This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 11
  • /
  • TGA(Australia) approves Vazkepa to reduce the risk...
News

TGA(Australia) approves Vazkepa to reduce the risk of cardiovascular events in adult statin- treated patients.- Amarin Corpn.

Read time: 1 mins
Published:20th Nov 2022

Amarin Corporation plc announced that Australia’s Therapeutic Good Administration (TGA) has granted approval to Vazkepa (icosapent ethyl).

The TGA approved Vazkepa to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk with elevated triglycerides in Australia. Dyslipidemia is a significant healthcare issue for patients in Australia. According to estimates from the most recent large-scale biomedical survey of the Australian population,1 nearly 2 in 3 people aged 18 and older have dyslipidemia, and one in seven people have high triglycerides in Australia.

The approval in Australia marks the fifth regulatory approval for the Vascepa/Vazkepa franchise in key international markets in 2022. In line with our international expansion strategy, Amarin is committed to partnering in these markets to commercialize the product.

Condition: Cardiovascular Events
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.